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Objective Prolonged neonatal jaundice is common 
and usually benign; however, assessment of bilirubin 
fractions is recommended to determine the need for 
further assessment for congenital liver disease, particularly 
biliary atresia. The direct (conjugated) bilirubin thresholds 
currently used are variable and poorly evidenced. Hence, 
we aimed to delineate direct bilirubin levels in disease-free 
neonates with prolonged jaundice.
Methods We performed a retrospective cohort analysis 
of split bilirubin levels, and subsequent follow-up, for all 
neonates initially assessed in our prolonged neonatal 
jaundice clinic over 2 years. We plotted centile charts for 
total, direct and direct–total bilirubin ratio levels against 
age at sampling. The association was assessed using 
linear regression analysis.
results Data were collected for 420 neonates (501 
blood samples) across an age range of 10–70 days. No 
significant liver disease was found. For each day of older 
age, total bilirubin fell by 3.72 µmol/L (95% CI 2.46 to 
5.00) and direct bilirubin fell by 0.39 µmol/L (0.18 to 0.59). 
The ratio between the two did not change significantly 
(−0.0006 to +0.0034). The 95th centile for direct bilirubin 
was stable at ~25 µmol/L. Direct–total bilirubin ratio was 
very variable with some 95th centiles >30%.
Conclusions In a clinically relevant population of 
disease-free neonates with prolonged jaundice both the 
total and the direct bilirubin decreased with age. The 
absolute direct bilirubin is more useful clinically than the 
direct–total bilirubin ratio. Our results support National 
Institute for Health and Care Excellence guidance that 
conjugated bilirubin >25 µmol/L, or even more stringent 
criteria, constitutes an appropriate threshold for further 
investigation for neonatal liver disease.
bACkgrOund
Prolonged neonatal jaundice is yellowing 
of the skin and sclerae, secondary to hyper-
bilirubinaemia, persisting beyond 14 days 
after birth. It is very common—20–30% 
of breastfed neonates are still jaundiced 
at 1 month1—and is usually transient and 
benign; however, it can be an important 
indicator of serious underlying pathology.2 
The most common cause is physiological 
jaundice (especially in breastfed neonates), 
but a number of disease processes must 
be excluded, including haemolysis, sepsis, 
hypothyroidism, cystic fibrosis, metabolic 
disease and liver disease (mainly congen-
ital hepatitis B/C or biliary atresia).3 It is 
particularly important to diagnose biliary 
atresia as, although rare, it is the only cause 
that is usually asymptomatic but in which 
early specialist assessment and surgery 
(Kasai portoenterostomy; ideally within 6–8 
weeks of age) are crucial for prognosis.4 
The abnormality of the biliary tree causes 
an obstructive jaundice with conjugated 
(direct) hyperbilirubinaemia, whereas 
What is already known on this topic?
 ► Biliary atresia and other congenital liver diseases 
are distinguished from physiological prolonged 
neonatal jaundice as they are associated with 
conjugated (direct), rather than unconjugated, 
hyperbilirubinaemia.
 ► The natural history of the total bilirubin level in the 
first 4 weeks of life in disease-free neonates is to 
decrease over time.
 ► The criteria currently recommended for further 
investigation in cases of prolonged neonatal 
jaundice are variable and supported by little 
evidence.
What this study hopes to add?
 ► In disease-free states, direct bilirubin decreases 
with age, particularly at the level of the 
individual. We produce centile charts that may 
serve as reference tools.
 ► However, the direct–total bilirubin ratio shows 
no clear trend and thus is an unreliable marker 
of serious pathology, including congenital liver 
disease.
 ► Our data support the NICE guidance advocating 
investigation for liver disease in neonates with 
conjugated bilirubin >25 µmol/L, although more 
stringent criteria may also be valid.
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physiological jaundice and almost all other pathological 
causes result in a predominantly unconjugated hyper-
bilirubinaemia.5 
Current National Institute for Health and Care Excel-
lence—the primary publisher of UK clinical guidelines 
(NICE)—guidance is that the cause of prolonged jaun-
dice requires investigation and referral for any neonate 
with a conjugated hyperbilirubinaemia >25 µmol/L, but 
this is based on no referenced data.2 The North Amer-
ican Society for Pediatric Gastroenterology, Hepatology 
and Nutrition (NASPGHN) recently released an updated 
guideline in collaboration with their European Society 
(ESPGHN) recommending further investigation under 
the definition of an abnormal direct bilirubin (a slight 
overestimate of conjugated bilirubin—see the Methods 
section) as >1.0 mg/dL (17.2 µmol/L).6 Their previous 
guideline, which also incorporated the direct–total bili-
rubin ratio, acknowledged that their thresholds are based 
on ‘lower quality studies’.7 And they now state that the 
move away from using the ratio is for simplicity rather 
than any novel evidence.6
We therefore sought to re-evaluate the poorly evidenced 
thresholds through characterising the natural history 
of both total and direct bilirubin levels. Total bilirubin 
levels have previously been shown to decrease reverse-ex-
ponentially with age in disease-free neonates,1 but to our 
knowledge the variation of direct bilirubin levels with age 
in this population is yet to be characterised (explaining 
the lack of evidence behind NICE’s 25 µmol/L cut-off).2 
Hence, our aims were to establish the spread of direct 
bilirubin levels in our sample and concordantly inform 
national guidance for the investigation of prolonged 
neonatal jaundice.
MethOds
sample population and data collection
We performed a retrospective cohort study of the last 460 
neonates who attended the prolonged neonatal jaundice 
clinic at the Royal Free Hospital (from December 2012 to 
November 2014). The community midwives were to refer 
all neonates who were visibly jaundiced at 14 days. The 
neonates referred were approximately 8% of the neonates 
in the community midwifery service. A paediatric nurse 
assessed all the neonates and took venous blood for 
split (total and direct) bilirubin. Further follow-up was 
arranged based on these results by criteria that, due to 
lack of confidence in local and national guidance (the 
impetus for this work), were decided by the responsible 
clinician on a case-by-case basis. The neonates’ date of 
birth and the results and dates of the initial split bilirubin 
as well as any further bilirubin measurements and further 
investigations (up until May 2015) were extracted from 
the hospital database and compiled. All these further 
investigations were assessed for abnormalities that may 
indicate underlying pathology (with particular focus on 
liver function tests and ultrasound imaging).
statistical analysis
To analyse trends at the population level, we calculated 
the age at time of testing from each neonate’s date of 
birth and the date of their split bilirubin measurement(s). 
The software used was SAS v9.3. The majority of our 
neonates were aged 14–30 days at testing (range 10–70). 
Table 1 shows the bilirubin measurements by age band, 
expressed as centiles. On testing (via histogram and Q-Q 
plot as well as numerical analysis with logarithmic conver-
sion for direct–total bilirubin ratio), the data were found 
to be normally distributed. We therefore plotted centile 
charts using mean and SD values (figure 1).
We also used linear regression to assess the association 
between bilirubin and age for all samples between 10 and 
42 days (96.8% of all samples), incorporating general esti-
mating equations to account for some neonates having 
more than one measurement.
Lastly, some neonates had two time-separated split bili-
rubins which allowed for limited analysis at the individual 
level.
biochemistry
Total and direct bilirubin on all samples was measured 
using the Roche/Hitachi 902 which employs diazo 
methods. Bilirubin in plasma exists in three forms: 
unconjugated bilirubin (reversibly bound to albumin; 
usually the major component), free conjugated bili-
rubin and delta bilirubin (conjugated bilirubin cova-
lently bonded to albumin; normal range approximately 
0.0–3.0 µmol/L). Using diazo methods for direct bili-
rubin, both conjugated and delta bilirubin are measured 
photometrically and thus the value is a little higher than 
conjugated bilirubin alone.8
results
sample population and data collection
Forty neonates had no successful investigations at all 
because they were either no longer deemed jaundiced 
by the nurses or the blood sample was insufficient for 
analysis. The remaining 420 had blood sampled for split 
bilirubin levels (419 with at least one total bilirubin; 418 
direct bilirubin). Further investigations were a repeat 
split bilirubin±further blood tests and liver ultrasound 
scan. The total number of times split bilirubin samples 
were taken was 501 (499 total bilirubin; 496 direct bili-
rubin). 359 children had one measurement, 46 had two, 
10 had three and 5 had four. None of the neonates we 
investigated further (eg, additional bloods and imaging) 
were found to have liver disease (ie, all liver function tests 
and ultrasound scans were not indicative of causation).
the population level
Figure 1A shows that, at the population level of disease-
free neonates with prolonged jaundice, the total bilirubin 
decreases noticeably with age at measurement in a similar 
curve to that described by previous studies1 with means 
around 150 µmol/L and 95th centiles of up to 250 µmol/L.
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Graphically, the direct bilirubin level appeared rela-
tively independent of age. Figure 1B shows that the mean 
remains close to 15 µmol/L and the 95th centile around 
25 µmol/L.
Figure 1C shows that the direct–total bilirubin ratio 
showed no clear trend and was very variable, especially 
across the 95th centile, with some values >30%.
Linear regression analysis showed that for each day of 
older age, total bilirubin fell by 3.72 µmol/L (95% CI 
2.46 to 5.00; P value <0.0001) and the direct bilirubin 
fell by 0.39 µmol/L (0.18 to 0.59; P value 0.0002). This 
equates to a 2.5%/day reduction from the approximate 
mean total bilirubin of 150 µmol/L and 2.6%/day from 
the approximate mean direct bilirubin of 15 µmol/L, 
respectively. The ratio between the two did not change 
significantly (95% CI −0.0006  to +0.0034; P value 0.1659).
the individual level
Sixty neonates had two complete split bilirubin samples 
taken. The first sample was taken at a median of 17 days 
(range 10–63) and the second at a median of 25 days 
(range 18–70). The median number of days between 
samples was 5 days (range 1–24). The median value 
of the first sample was a total bilirubin of 164 µmol/L 
(range 12–318), direct bilirubin of 14 µmol/L (1–32) 
and direct–total bilirubin ratio of 0.087 (0.007–0.500). 
In these neonates, the mean change between samples 
in total bilirubin was −10 µmol/L (95% CI −137,+68; 
P value<0.0001) and in direct bilirubin was −4.5 µmol/L 
(95% CI −22,+22; P value<0.0001). This equates to an 
average 1.2%/day reduction from initial total bilirubin 
and 6.4%/day reduction from initial direct bilirubin. On 
the other hand, the direct–total bilirubin ratio did not 
change significantly at −0.002 (95%  CI -0.096,+0.179; 
P value 0.8785).
We note that this group of neonates cannot be consid-
ered the same as those who had only one sample taken. 
In comparison, neonates with more than one split bili-
rubin sample have, on average, 27% higher total bili-
rubin (P=0.0002), 6% higher direct bilirubin (P=0.0370) 
and 30% higher direct–total bilirubin ratio (P=0.0067).
disCussiOn
We consider our data to be an accurate, novel and clin-
ically significant description of split bilirubin levels in 
a population of disease-free neonates referred with 
prolonged jaundice. None of the neonates we did inves-
tigate further were found to have significant liver disease. 
Indeed, no neonates in the study have relevant subse-
quent abnormal liver function tests recorded on our 
system—which due to biliary atresia’s aggressive course 
would almost certainly not go unrecorded. It is unlikely 
that there was a subsequent diagnosis of biliary atresia of 
which we were not aware as neonates in our area having 
surgery for biliary atresia return to our community 
nursing service for follow-up care. We acknowledge that 
as we are a London centre it is possible for a neonate to 
have presented to a nearby service with a liver problem 
of which we were unaware. However, the incidence of 
biliary atresia is 1:18 000 in the general population4 or a 
maximum of 1:1500 in our sample (8% of those in our 
community midwife service). Therefore, the likelihood 
of a neonate(s) with biliary atresia being present in our 
sample and not detected by us is exceptionally low and 
in any case would exert minimal skew on the trends 
observed.
Our sample is not representative of the normal popu-
lation, rather it is a description of the population of 
Figure 1 Bilirubin centile charts versus age at measurement 
calculated from mean and SD values (assuming normal 
distribution). (A) Total bilirubin, (B) direct bilirubin and (C) 
direct–total bilirubin ratio.
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neonates with prolonged jaundice—this is the clinically 
relevant group regarding which clinicians must make 
decisions. Nonetheless, it is reassuring that our results 
concord with existing data. Maisels et al, a team from 
Oakland University, describe the natural history of total 
bilirubin levels (transcutaneous) in a breastfed popu-
lation.1 The total bilirubin values in our neonates were 
higher, as expected in a population referred for visible 
jaundice, but our data decreased with age along a similar 
trend.
We also plotted the direct bilirubin level against age, 
which has not been done previously. At the popula-
tion level in the age range 11–42 days inclusive (96.6% 
of sample), graphically the direct bilirubin appeared 
relatively constant with a mean of 15 µmol/L and a 
95th centile value of approximately 25 µmol/L. Linear 
regression analysis showed that direct bilirubin decreases 
with age, but nonetheless values of direct bilirubin up to 
25 µmol/L are seen in disease-free neonates at 2–6 weeks 
of age. Clinicians may wish to use figure 1 as a reference 
tool during their practice.
Our direct bilirubin values are generally higher 
than those found in previous population studies which 
have been based on neonates in the first 2 weeks of 
life. Previous work from Birmingham has shown the 
97.5th centile for direct bilirubin measured in routinely 
collected screening specimens of approximately 27 000 
neonates at 6–10 days was 21 µmol/L.9 Davis et al 10 found 
96% of approximately 70 000 neonates undergoing 
clinically indicated split bilirubin measurements had a 
maximum conjugated bilirubin <17 µmol/L in the first 
2 weeks of life. Although the neonates in these studies 
were less than 14 days of age, this appears to be the only 
evidence informing current advice regarding investiga-
tion of prolonged jaundice.2 7 Combining our data with 
previous studies suggests that the direct bilirubin tends 
to rise in the first 2 weeks of life, but thereafter decreases 
slowly in disease-free neonates.
We also calculated the direct–total bilirubin ratio. 
Linear regression analysis found no significant change 
with age. The 95th centile values were particularly vari-
able with some >30% and so the direct–total bilirubin 
ratio used alone is unlikely to be a reliable marker of 
pathology.
Sixty neonates had two complete split bilirubin 
samples, allowing us limited interpretation of trends 
over time at the individual level. Both total and direct 
bilirubin levels decreased significantly (P values 
<0.0001)—direct bilirubin by a mean of 4.5 µmol/L 
over a median of 5 days—while the direct–total bili-
rubin ratio showed no significant trend (P value 
0.8785). The average drop in direct bilirubin was 
6.4 %/day compared with 2.6 %/day at the popula-
tion level. Therefore, failure for direct bilirubin to 
decrease in an individual must be taken particularly 
seriously. There is, however, a bias towards these indi-
viduals having higher bilirubin levels than those with 
only one sample taken. Of interest, this was more 
marked with direct–total bilirubin ratio (30% greater) 
than direct bilirubin (6% greater), thus highlighting 
that practitioners continue to consider a raised 
ratio more significant (warranting further investiga-
tions, including repeat split bilirubin) than a raised 
direct bilirubin which, as discussed above, may be 
inappropriate.
Our study does not allow calculation of a defini-
tive threshold for direct bilirubin below which biliary 
atresia or other significant congenital liver disease 
can be excluded. However, there are data on the rise 
in direct bilirubin in neonates less than 2 weeks of 
age found to have biliary atresia demonstrating levels 
well above 25 µmol/L. Harpavat et al11 found that 
the mean direct bilirubin in 34 neonates with biliary 
atresia was 25 µmol/L at 24–48 hours and 45 µmol/L 
at 72–96 hours. Terui et al12 noted a direct bilirubin 
level of around 90 µmol/L at 2–3 weeks of age in 19 
neonates with biliary atresia. Siu and colleagues13 
reported a mean direct bilirubin of 142 µmol/L in 
20 neonates aged less than 3 months (median 45 
days) with biliary atresia. According to our data (see 
figure 1B), a threshold of 25 µmol/L would result 
in investigation of roughly 5% of all neonates with 
prolonged jaundice and seem to carry little risk of 
missing a case of biliary atresia.
This threshold may even contain a large safety 
margin. Many centres will measure direct bilirubin, 
where a threshold of 25 µmol/L would actually 
reflect a more conservative conjugated bilirubin of 
22–25 µmol/L. Furthermore, there is a published 
audit of a prolonged jaundice service in the UK.14 
The protocol for further investigation was a direct 
bilirubin >18 µmol/L and >20% of total. Ten of 882 
(1.1%) neonates tested positive on this measure; eight 
of whom were confirmed to have neonatal liver disease. 
None of the others went on to receive such a diagnosis. 
Thirty-three other neonates were diagnosed with liver 
disease outside of the prolonged jaundice service, but 
within the study area during the audit period, and all 
also met the criteria—the authors conclude that their 
criteria are 100% sensitive for liver disease. Our data 
suggest that 5% of neonates with prolonged jaundice 
have direct bilirubin levels above 25 µmol/L—ap-
proximately 4.5 times greater than the 1.1% satisfying 
Cartledge’s criteria. Their investigation threshold must, 
therefore, have been more stringent than that recom-
mended by NICE, but still failed to miss a single case 
of neonatal liver disease.
COnClusiOn
In a clinically relevant population of disease-free 
neonates referred with prolonged jaundice, we found 
the 95th centile for direct bilirubin decreased slowly 
with age but was approximately 25 µmol/L. Failure 
for direct bilirubin to decrease with time at an indi-
vidual level is particularly concerning. In contrast, 
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the direct–total bilirubin ratio was highly variable 
and hence an unreliable indicator of pathology. 
While we acknowledge our data do not include any 
patients with liver disease, they nonetheless provide 
support for the NICE recommendation that well 
neonates with prolonged jaundice do not require 
investigation for liver disease if the conjugated bili-
rubin is ≤25 µmol/L.2 This threshold has the merits 
of simplicity and a high margin of safety; however, 
compared with other more stringent criteria,14 it may 
result in more neonates being extensively investigated 
with negligible gain in sensitivity.
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